Data on investigational obexelimab and frexalimab, blood neurofilament light chain as a marker for treatment response, and benefits of ofatumumab are highlighted findings in relapsed-remitting ...

U.S. President Donald Trump alluded to Section 301, 232 and 122 tariffs during his press conference on Friday (February 20, 2026) after the U.S. Supreme Court said his use of emergency powers granted ...

The law has survived the dot-com bubble and the Supreme Court, but it’s up against potentially larger challenges. The law has survived the dot-com bubble and the Supreme Court, but it’s up against ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. "I ...

Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...

On September 25, 2025, the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) upheld Lists 3 and 4A of Section 301 tariffs on Chinese products. Should the Federal Circuit’s decision ...

Great news for taxpayers! On August 12, 2025, the Income Tax Appellate Tribunal (ITAT) Ahmedabad bench allowed a taxpayer to claim Section 87A tax rebate on short term capital gains (STCG) under the ...

Operations develop a new strategy in the last year of the current one and submit the new strategy to the plan approver in April. Guidance on developing operations’ budget is detailed in PLAN – Section ...

$54.5 million in seed financing led by founding investor 5AM Ventures alongside Atlas Venture, OrbiMed and Qiming Venture Partners USA BERKELEY, Calif.--(BUSINESS WIRE)--Renasant Bio (Renasant), ...

Seyfarth Synopsis: On July 1, 2025, OFCCP published in the Federal Register a set of proposals to rescind the regulations implementing Executive Order 11246 and to modify the regulations implementing ...